WallStreetZenWallStreetZen

NASDAQ: MIST
Milestone Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for MIST

Based on 2 analysts offering 12 month price targets for Milestone Pharmaceuticals Inc.
Min Forecast
$5.00+233.33%
Avg Forecast
$15.00+900%
Max Forecast
$25.00+1,566.67%

Should I buy or sell MIST stock?

Based on 2 analysts offering ratings for Milestone Pharmaceuticals Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MIST stock forecasts and price targets.

MIST stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-30
lockedlocked$00.00+00.00%2024-03-05
lockedlocked$00.00+00.00%2023-12-27

1 of 1

Forecast return on equity

Is MIST forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.85%

Forecast return on assets

Is MIST forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

MIST revenue forecast

What is MIST's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.8M
Avg 2 year Forecast
$5.5M
Avg 3 year Forecast
$51.6M

MIST vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MIST$1.50$15.00+900.00%Strong Buy
CUE$1.63$8.00+390.80%Strong Buy
ENTX$2.25$10.00+344.44%Buy
SER$9.41N/AN/A
ONCY$1.07$4.00+273.83%Buy

Milestone Pharmaceuticals Stock Forecast FAQ

Is Milestone Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MIST) stock is to Strong Buy MIST stock.

Out of 2 analysts, 1 (50%) are recommending MIST as a Strong Buy, 1 (50%) are recommending MIST as a Buy, 0 (0%) are recommending MIST as a Hold, 0 (0%) are recommending MIST as a Sell, and 0 (0%) are recommending MIST as a Strong Sell.

If you're new to stock investing, here's how to buy Milestone Pharmaceuticals stock.

What is MIST's revenue growth forecast for 2024-2026?

(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Milestone Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MIST's revenue for 2024 to be $95,868,841, with the lowest MIST revenue forecast at $95,868,841, and the highest MIST revenue forecast at $95,868,841. On average, 3 Wall Street analysts forecast MIST's revenue for 2025 to be $294,690,164, with the lowest MIST revenue forecast at $95,868,841, and the highest MIST revenue forecast at $575,213,044.

In 2026, MIST is forecast to generate $2,748,240,097 in revenue, with the lowest revenue forecast at $2,748,240,097 and the highest revenue forecast at $2,748,240,097.

What is MIST's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: MIST) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is MIST's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MIST price target, the average MIST price target is $15.00, with the highest MIST stock price forecast at $25.00 and the lowest MIST stock price forecast at $5.00.

On average, Wall Street analysts predict that Milestone Pharmaceuticals's share price could reach $15.00 by May 30, 2025. The average Milestone Pharmaceuticals stock price prediction forecasts a potential upside of 900% from the current MIST share price of $1.50.

What is MIST's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: MIST) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.